We provide you with 20 years of free, institutional-grade data for AFMD stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of AFMD. Explore the full financial landscape of AFMD stock.
| Reported Date | CIK | Ticker | Type |
|---|
Affimed(NASDAQ:AFMD) 
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which has completed Phase 2a clinical study of relapsed CD30-...
Website: http://www.affimed.com
Founded: 2000
Full Time Employees: 137
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about AFMD stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.